Kornimate/medical-research-clean huggingface dataset:
computational drug repurposing for all ebs cases

Conditions: Epidermolysis Bullosa; Healthy; Genetic Skin Disease; Epidermolysis Bullosa Simplex; Epidermolysis Bullosa, Junctional; Epidermolysis Bullosa Dystrophica

Summary: the study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of eb, as well as normal skin from non-eb subjects. state of the art computational analysis will be performed to help identify new drugs that might help all eb wound healing and reduce pain. researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of eb. drug development is a very expensive process taking decades for execution. drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. to date, there is no specific treatment targeting the physiology and immunologic response in eb patients during wound healing. market availability of repurposed medications will provide all eb patients rapid access to treatments, thus improving their quality of life.

although gene, cell, and protein-based therapies are in development for patients suffering from all subtypes of epidermolysis bullosa (eb), new pharmacological treatments are in dire need. characterizing molecular changes in eb, including gene expression, can identify new therapeutic targets and drugs that modulate those targets. however, sifting through gene expression information to identify the most promising drug targets is a complex data challenge. the goal of the study will identify a computational approach to evaluate and identify existing drugs approved for other diseases that can be repurposed for eb patients. the study will perform an unprecedented characterization of gene expression changes in eb patients compared to healthy, non-eb individuals across multiple tissues. using a validated computational drug discovery platform, researchers will analyze gene expression and drug data using unique algorithms. in the first year, a list of ten, safety drugs more probable to treat the eb disease state will be identified. the most promising drugs discovered will then be tested in the clinic setting.

Eligibility criteria:
inclusion criteria: * subjects of all ages * diagnosis of all subtypes of eb subjects * healthy, non-eb subjects * ability to complete study visit to collect tissue and blood specimen exclusion criteria: * pregnancy, breast feeding * prior history of liver disease * serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent tissue collection from subjects

Keywords: epidermolysis bullosa genetic expression drug repurposing computational approaches drug discovery
inspiratory muscle training in patients with interstitial lung disease

Conditions: Interstitial Fibrosis; Pulmonary Disease; Interstitial Lung Disease; Sarcoidosis; Idiopathic Pulmonary Fibrosis; Pneumonia, Interstitial

Summary: the aim of this study is to evaluate the effects of inspiratory muscle training program in inspiratory muscle endurance, breathlessness, inspiratory muscle strength, functional capacity and quality of life in patients with interstitial lung disease. patients are evaluated before the inspiratory muscle training and after 8 weeks of training.

inspiratory muscle training has been described as an effective intervention and contribute to the improvement of inspiratory muscle function and breathlessness in patients with chronic lung disease. the aim of this study is to evaluate, the effects of inspiratory muscle endurance, breathlessness, inspiratory muscle strength, functional capacity and quality of life in patients with interstitial lung disease. it is a quasi-experimental study. patients with interstitial lung disease are recruited from interstitial disease ambulatory. in each session patients performs two times 30 breaths with a minute rest between them. the load is set according with 50% of actual pimax, the borg score should be between 4 and 6, otherwise the load will decrease (if borg more than 6) or increase (if borg less than 4). new pimax is measured weekly and the new load is defined following the same protocol for 8 weeks. patients are evaluated before the inspiratory muscle training and after 8 weeks of training.

Eligibility criteria:
inclusion criteria: * clinical and radiological diagnosis of interstitial lung disease established by a pulmonologist; * absence of clinical exacerbations of the disease in the four weeks prior to the initial data collection; * present medical research council scale more than 2; * absence of a associated or self reported cardiac, orthopedic and psychiatric diseases, * not participating in pulmonary rehabilitation programs; * do not use supplemental oxygen therapy while resting. exclusion criteria: - inability of the participant to understand or perform the procedures proposed during the evaluations and training program.

Keywords: inspiratory muscle training interstitial lung disease inspiratory muscle endurance breathless
effects of novel breathing behavior modification yoga positioning integrated program on weight loss

Conditions: Weight Loss; Metabolism

Summary: this study is to evaluate the physical and cognitive effects of a 15 min per day novel breathing and mindfulness moving-meditation program on metabolism, cognition, and emotion health. it is thought that the breathing and movement program will increase basal metabolism, facilitate fat loss, and decrease depressive behaviors. anthropometric, blood chemistries, and cognitive measures of depression, sleep, and hunger will be measured over a two-month interventional program.

subjects will be randomized into two groups, an active group and control group. for the first 30 days, the active group will follow the movement/breath program and the controls will be instructed not to change their lifestyle (no change in diet, and no change in exercise / physical activities). the technicians taking measurements will be blinded as to which participants are actives vs controls. the following 30 days' intervention will consist of continuing the phase i interventions combined with implementing the behavior change strategies on 2 to 3 habit changes self-selected from a list of 30 top "bad habits" that contribute to weight gain and undermine one's ability to lose weight with the control group again not changing any lifestyle activities. measurements: measurements will be taken at the start (baseline), 10 days, 30 days, and 60 days of intervention with the measurement days scheduled to evaluate people completing 10 full days of the program, 30 full days, and 60 full days respectively. measurements taken at each interval to include weight, body composition (lean mass \& fat percentages), anthropometric measurements (umbilicus, hips, right thigh, right upper arm), po2, resting heart rate, hrv, blood pressure, pulmonary health (i.e., o2 max, spirometry), hunger, sleep, and depression rating (by self-assessment survey scale). serum chemistry for basic metabolic panel, inflammatory markers, and lipids, hematology for oxygen carrying capacity and gross immune response, human growth factor production via elisa quantification, imaging ultrasound to measure subcutaneous fat thickness at the areas of girth measurements, dexa for overall and targeted areas body composition, and resting metabolic rate via oxygen plethysmograph.

Eligibility criteria:
inclusion criteria * age 18-70 years * body mass index at or above 27 * stable weight past 3 months * able to stand for 10 minutes * able to lift arms overhead exclusion criteria: * chronic obstructive pulmonary disease * acute respiratory distress * supplemental oxygen use * inability to stand, flex trunk, or move arms overhead * pacemaker implant * taking beta blocking medications.

Keywords: metabolism obesity mentation
extension study evaluating antibody persistence and safety, tolerability and immunogenicity of a booster dose of novartis rmenb±omv nz vaccine in healthy uk children who previously received three doses of the same vaccine

Conditions: Meningococcal Disease

Summary: the proposed study v72p9e1 is an extension study of v72p9. the objectives of this extension study will be to explore antibody persistence in children at approximately 40 months of age and to evaluate the safety, tolerability and immunogenicity of a booster dose of rmenb±omv nz administered to subjects at approximately 40 months of age. antibody persistence will be subsequently measured at 18-20 months after these booster doses when the subjects are 60 months of age. two groups of naïve subjects, aged approximately 40 and 60 months, will be recruited in the study to serve as a baseline comparator for assessing antibody persistence at these ages. these subjects will receive a two-dose catch-up regimen with rmenb+omv nz. subjects who are enrolled at 40 months of age are offered dtap/ipv and mmr vaccinations , if they have not already received these vaccines prior to enrollment.


Eligibility criteria:
inclusion criteria: * healthy 40 to 44-months-old children, who participated and completed the study v72p9 (follow-on subjects) * healthy 40 to 44-months or 60 to 62-months-old children (naïve subjects) exclusion criteria: * previous ascertained or suspected disease caused by n meningitidis * history of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component * any serious chronic or progressive disease * known or suspected impairment/ alteration of the immune system * receipt of, or intent to immunize with another vaccine, within 30 days prior and after vaccination with the investigational vaccines (within 14 days for licensed flu vaccines)

Keywords: children pre-school meningococcal disease prevention vaccination
cervical parameters and body awareness in relation to smartphone addiction

Conditions: Smartphone Addiction

Summary: the study was planned as a observational, cross-sectional study


Eligibility criteria:
inclusion criteria: * being a smartphone user * being between the ages of 18 and 25 exclusion criteria: * neck pain * radicular pain * neurological symptoms * cervical surgery or cervical trauma

Keywords: smartphone cervical vertebrae range of motion pain
transversal multiaxial evaluation and 5-year follow-up of a cohort of french gamblers (jeu)

Conditions: Pathological or "at Risk" Gambling

Summary: this study is divided into two stages. the first stage is a transversal study and corresponds to the recruitment of participants, which will last about two years. three groups of gamblers will be constituted : non-problematic gamblers (npg), problematic gamblers not in care (pgnc) and problematic gamblers in care (pgc).the second stage is a prospective 5-year follow-up study of the cohort (only the initial npg and pgnc groups are concerned by the follow-up study), that consists on an annual follow-up evaluation. the main objective of the first stage of the study is to compare the characteristics of the three groups of gamblers on some socio-demographic and clinical data. these comparisons will allow us to identify, among all data, those that will be most likely to explain the evolution of the practice of gambling (appearance or resolution of a gambling problem), and recourse to specific care. these such isolated data will be tested in the second stage of the study, in order to determine those that are predictive factors of three steps of the gambling course of some gamblers : evolution of a controlled gambling practice into a problematic gambling practice, resolution of the problematic gambling practice without intervention of care, and first recourse to specific care.


Eligibility criteria:
inclusion criteria: * to be 18 to 65 years old * to have gambled during the last year * to gamble at least one time a year exclusion criteria: * to be under tutelage (a french protecting measure for persons with altered judgement) * to present obvious cognitive disturbances * to have difficulties to read and/or write in french language

Keywords: pathological gambling "at risk" gambling gambling practice evolution psychiatric comorbidities gambling trajectory cognitive distortions adhd addiction recourse to care
ulcerative colitis endoscopic index of severity and fecal calprotectin to predict the reaction to corticosteroids of acute severe ulcerative colitis

Conditions: Acute Severe Colitis (ASC)

Summary: for acute severe colitis (asc) patients, corticosteroids (cs) was recommended as the first-line treatment in the guideline, but patients have a great risk of requiring colectomy or turning to second-line treatment. this study aim to verify the effectiveness of ulcerative colitis endoscopic index of severity(uceis) in predicting the reaction to corticosteroids, and explores the possibility that noninvasive marker fecal calprotectin (fc) could act as an alternative to uceis.


Eligibility criteria:
inclusion criteria: 1. patients with a confirmed diagnosis of asc according to truelove and witt's criteria; 2. patients were generally able to tolerate the flexible colonoscopy before start of cs treatment; exclusion criteria: 1. patients with incomplete colonoscopy, inadequate fecal sample; 2. patients with indeterminate diagnosis of asc (colorectal cancer, crohn's disease) according to colonoscopy; 3. patients with infectious colitis, clostridium difficile and cmv infection, primary immunodeficiency, recent history of immunosuppressant within 3 months. 4. patients with bowel resection, intestinal anastomotic, and ileum enterostomy.

Keywords: acute severe colitis corticosteroids uceis fecal calprotectin
testing cbt models and change mechanisms for alcohol dependent women

Conditions: Alcohol Use Disorder

Summary: the study has 4 specific aims: (1) to modify our existing individual female specific cognitive behavioral therapy (i-fs-cbt) for alcohol use disorder (aud) approach to treat women with alcohol dependence in a group format, group female specific cognitive behavioral therapy (g-fs-cbt); (2) to test the relative efficacy of i-fs-cbt and g-fs-cbt; (3) to test hypothesized mechanisms of change in drinking that are common to both treatments, including (a) coping skills and enhanced self-efficacy for abstinence; (b) enhanced sense of autonomy; (c) alleviation of negative affect, and (d) increased social network support for abstinence, and (4) to assess the relative cost-effectiveness of the individual and group treatment.

participants completed a telephone screen for initial eligibility and were scheduled for an in-person clinical intake interview. consented women were scheduled for a baseline research interview (bl) approximately one week later. at the end of the bl, participants were randomized to treatment condition. during the 12 session treatment period, women completed assessments at the beginning and end of each therapy session on secondary outcome and therapy process variables. in i-fs-cbt each participant saw a therapist weekly. the first session was 90 minutes long, and subsequent sessions were 60 minutes long. the i-fs-cbt manual included core cbt, motivational enhancement, and relapse prevention components. two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence and (b) self-care. the g-fs-cbt manual included material identical to i-fs-cbt, but the session organization was modified for a closed group format. the group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence. the first session of g-fs-cbt was 2 hours; remaining sessions were 90 minutes. in-person follow-up interviews were done at 3, 9, and 15 months post-session 1.

Eligibility criteria:
inclusion criteria: * age 18 or older * have a current (past year) diagnostic and statistical manual-iv (dsm-iv) alcohol dependence diagnosis * used alcohol in the 60 days prior to telephone screening exclusion criteria: * have psychotic symptoms in the past six months * gross cognitive impairment * current physiological dependence on any illicit drug

Keywords: alcohol use disorder women female specific therapy cognitive behavior therapy group therapy
examination of left atrial fibrosis using mri

Conditions: Fibrosis

Summary: this study evaluates images obtained from a standard clinical cardiac mri for evidence of fibrosis.


Eligibility criteria:
inclusion criteria: * 18+ years of age * being scheduled for a standard of care mri exclusion criteria: - patient unable to provide informed consent
proprioceptive isokinetic repositioning, functional testing, and a self-reported questionnaire before and after anterior cruciate ligament reconstruction

Conditions: ACL Tear; ACL - Anterior Cruciate Ligament Deficiency

Summary: this prospectively study aims to evaluate the evolution of knee joint proprioception on isokinetic dynamometer before and after anterior cruciate ligament (acl) reconstruction and its relationships with muscle strength, self reported questionnaire and return to sport. this study will include 30 athletes with isolated acl rupture, and treated with acl reconstruction surgery and 15 healthy volunteers.

anterior cruciate ligament (acl) rupture is a common injury in athletes. it has multiple consequences on the knee: instability, pain, loss of muscle strength, proprioceptive impairments, modification of the knee kinematics and premature knee osteoarthritis. in athletes, the majority of these injuries are treated with acl reconstruction surgery. the main objective of this treatment is the reduction of knee instability to allow return to sport, and this at the same level prior to the injury. thus, the athlete's follow-up after the surgery is essential to guide the return to sport and to ensure that the knee sensorimotor control allows the return to sport. currently this assessment is based primarily on functional testings and measurement of muscle strength. the investigators propose to prospectively study the evolution of instrumentally measured knee proprioception using isokinetic dynamometer before and after acl reconstruction as well as a study of the factors associated with its favorable evolution and its impact in the return to sport and its level.

Eligibility criteria:
inclusion criteria: * isolated and primary tear of the acl * individual candidate for an acl reconstruction surgery. * acute acl injury (\<6 weeks) * athletes (person who competes in one or more sports that involve physical strength, speed or endurance) whatever their level of sport practice * internet access exclusion criteria: * prior knee surgery * complex ligamentous lesion (lateral ligaments, posterior cruciate ligament) * surgery for meniscal lesions (patients initially included but warranting meniscal surgery during arthroscopy will be secondarily excluded from the study.) * recent muscle damage * history of significant injury on the healthy knee * acl rupture recurrence * pregnant woman * neurological or vestibular antecedent with sequelae * individuals taking treatment altering alertness (neuroleptics, sedatives) * informed consent not obtained
safety and effectiveness of prx-08066 in patients with pulmonary hypertension and chronic obstructive pulmonary disease

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease

Summary: this study is being conducted to see if prx-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: 1. 25 to 79 years old. 2. provide voluntary written informed consent to participate. 3. smoking history of at least 10 pack years (1 pack of cigarettes per day for 10 years). 4. diagnosis of chronic obstructive pulmonary disease. 5. become short of breath with physical activity. 6. elevated systolic pulmonary artery pressures. 7. not pregnant, nursing, or planning a pregnancy. exclusion criteria: 1. left ventricular ejection fraction \<30%. 2. heart attack or stroke within the last 6 months. 3. history of lung resection surgery. 4. use of supplemental oxygen \>20 hours/day. 5. blood donation or significant blood loss within the last 56 days. 6. plasma donation within the last 14 days. 7. use of any drugs for another research study within the last 30 days. 8. use of vasodilators, long acting nitrates, prostacyclin analogs, endothelin antagonists, or phosphodiesterase inhibitor drugs within the last 14 days. 9. positive blood screen hepatitis b surface antigen (hbsag) or hepatitis c antibody. 10. major surgery within the last 28 days. 11. any other medical condition that may jeopardize the safety of the subject, the validity of the study results, or interfere with the completion of the study according to the protocol.

Keywords: pulmonary hypertension ph pulmonary arterial hypertension pah chronic obstructive pulmonary disease copd prx-08066 predix
do patients with fish or shellfish allergy tolerate the consumption of fish oil supplements? a clinical study

Conditions: Food Hypersensitivity

Summary: the purpose of this clinical study is to test whether patients with fish or shellfish allergy can ingest different types of fish oil supplements without having an allergic reaction. to achieve this, the recruited participants will be asked to: * provide a blood sample (used for basophil histamine release assay) * undergo a skin-prick-test * partake in multiple oral provocations these three tests will indicate the likelihood that the participants can consume fish oil supplements without adverse allergic reactions (see the detailed description for an explanation of the tests). the investigators will test the participants tolerance for three different types fish oil supplements: fish oil, cod liver oil, and krill oil.

the basophil histamine release assay is a test that indicates whether or not the immune cells of the participant reacts when it comes into contact with the fish oils. the skin-prick-test involves the participants having their skin exposed to the fish oils. this is done by first exposing a tiny needle to the given fish oil, and then pricking the needle into the skin on the forearm of the participant. in this way, the immune cells of the skin is exposed to the fish oils. if an allergic reaction occurs, the pricked skin will swell and turn reddish. during the oral provocation, the participant is asked to ingest small, but increasing, doses of the fish oils over a period of 2 hours. the provocation will end when either an allergic reaction occurs or the participant has ingested a total dose of 5 ml fish oil.

Eligibility criteria:
inclusion criteria: * adult (≥18 years old) * legally competent * understands danish exclusion criteria: * current use of antihistamine, immunosuppressants, and/or anti-ige-treatment that cannot be safely terminated during the study period * the presence of severe diseases such as: cardiovascular disease, asthma, cancer, liver disease, kidney disease, hematological diseases, neurological diseases, dementia, immunological diseases, and endocrine diseases * chronic urticaria * severe atopic eczema * pregnancy and/or breastfeeding * participation in another clinical study the previous three months * known excessive use of alcohol and/or substance abuse